Surgery plus medication for liver cancer that has spread
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding systemic therapy (anticancer drugs) to surgery helps people with liver cancer that has spread to other parts of the body. It aims to improve outcomes by treating both the liver tumor and the metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer)
- Your liver tumor can be removed with surgery, and your liver function is good (Child-Pugh class A or stable B7)
- You have at least one measurable tumor outside the liver that can be evaluated
- You have not received any prior systemic treatment (like immunotherapy, targeted therapy, or chemotherapy) for your liver cancer
- You are generally in good health (able to do light activity) and willing to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests whether removing the spleen (splenectomy) can improve the effectiveness of targeted therapy and immunotherapy for people with advanced liver cancer (HCC) who also have enlarged spleens due to portal hypertension. It aims to see if this combination can help control the cancer better.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.